You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

DISCOVER RELVAR

Don’t let asthma control your patients

Keep asthma tamed through proactive control that lasts with Relvar.

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting β2-agonists.
  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.1

Why choose Relvar?

Tick icon

25% more patients see improvement vs other commonly used ICS/LABAs*2

24-H icon

Sustained efficacy for 24 hours and long-lasting anti-inflammatory effect3-5

Ellipta device icon

Good adherence with an easy-to-use device1,6,7

Safety Information

Relvar: well tolerated in asthma and COPD, with over 5 million patient-years of exposure8,9

Relvar has a generally well-tolerated safety profile9 with adverse events consistent with the ICS/LABA class of medications.9

See below for a brief summary of adverse events associated with Relvar. Full details can be found in the Relvar Summary of Product Characteristics.

Very common adverse events (≥1/10)11

Common adverse events (≥1/100 to <1/10)11
  • Headache
  • Nasopharyngitis
  • Pneumonia
  • Upper respiratory tract infections
  • Bronchitis
  • Influenza
  • Candidiasis of mouth and throat
  • Oropharyngeal pain
  • Pharyngitis
  • Rhinitis
  • Sinusitis
  • Cough
  • Dysphonia
  • Abdominal pain
  • Arthralgia
  • Back pain
  • Fractures
  • Pyrexia
  • Muscle spasm

Pneumonia risk in asthma11

Pneumonia risk in COPD11
In an integrated analysis of 11 studies asthma (n=7034), the incidence of pneumonia per 1000 patient-years was 18.4 for Relvar 184/22 mcg vs. 9.6 for Relvar 92/22 mcg and 8.0 for placebo9 In common with other ICS-containing medicines, there is an increased risk of pneumonia in COPD patients treated with these types of medicines. The incidence of pneumonia with Relvar is similar to that seen with other ICS/LABA combinations10

Important Product Information

Patient information

open

Summary of product characteristics

OPEN

Need help with this product?

Request a contact

From a sales representatives

Stay informed

Get the latest updates from GSK

Footnotes

*The primary endpoint was the proportion of patients who achieved an improvement in ACT score from baseline of ≥3 or a total ACT score of ≥20, in patients in the PEA population initiated on Relvar vs continuing on usual care (ICS or ICS/LABA) at 24 weeks. The primary endpoint was met (p<0.0001). Data presented are from a subset of patients prescribed ICS/ LABA at baseline who were initiated on Relvar or continued on their ICS/LABA. Data showed a relative difference of 25% and an absolute difference of 14%.2 In this study there was no difference in serious adverse events reported between Relvar and usual care. The most common serious adverse events of special interest were cardiovascular disease, asthma and bronchospasm, and pneumonia.2
*If using on average two doses per day.

Abbreviations

ACT, Asthma Control Test; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; PEA, primary effectiveness analysis; PRD, proactive regular dosing; COPD, chronic obstructive pulmonary disorder.

References
  1. Global Datasheet Fluticasone furoate/vilanterol: v11, May 2021.
  2. Woodcock A, et al. Lancet 2017;390:2247–2255.
  3. Bernstein DI, et al. J Asthma 2015;52:1073–1083.
  4. Braithwaite I, et al. Respir Med 2016;119:115–121.
  5. Bardsley G, et al. Respir Res 2018;19:133.
  6. Svedsater H, et al. NPJ Prim Care Respir Med 2014;24:14019.
  7. Parimi M, et al. Adv Ther 2020;37:2916–2931.
  8. GSK Data on File 16221; 2019.
  9. Global Datasheet Fluticasone furoate/vilanterol: v11, Accessed June 2023.
  10. Kew KM, et al. Cochrane Syst Rev 2014;3:CD010115.
  11. Relvar Ellipta SmPC, available at https://www.medicines.ie/medicines/list/all/page-1/per-page-25?query=relvar

RELVAR Ellipta was created in collaboration with

Innoviva logo

POM. Further information is available from GlaxoSmithKline (Ireland) Ltd

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

PM-IE-FFV-WCNT-250002 August 2025